» Articles » PMID: 35379274

Association Between Bone Turnover Markers, BMD and Height Loss of Cemented Vertebrae After Percutaneous Vertebroplasty in Patients with Osteoporotic Vertebral Compression Fractures

Overview
Publisher Biomed Central
Specialty Orthopedics
Date 2022 Apr 5
PMID 35379274
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Percutaneous vertebroplasty (PVP) was recently performed for treating patients with osteoporotic vertebral compression fractures (OVCF). However, recompression of cemented vertebra with significant vertebral height loss occurred in the patients after PVP was observed during the follow-up period. The purpose is to explore the risk factors among several potential predictors for the height loss of treated vertebral bodies after PVP in patients with OVCF.

Methods: A study of 93 patients who had undergone PVP between May 1, 2016, and March 1, 2019, at the Spine Center of Huadong Hospital Affiliated to Fudan University was conducted. The fractured vertebral height loss ratio ≥ 15% at final follow-up were defined as cemented vertebra recompression. The following variables were measured and collected: age, gender, body mass index (BMI), bone mineral density (BMD), volume of bone cement injected, bone cement leakage, fractured vertebra segment, contact between bone cement and endplates, serum of calcium and phosphorus, and six kinds of bone turnover markers.

Results: Mann-Whitney U test and Univariate Logistic regression analysis showed that the cemented vertebra recompression was correlated with BMD, contact between bone cement and endplates, parathyroid hormone (PTH), and 25-hydroxy vitamin D3 (25-OH-D3). Following multivariate modeling, multiple factors logistic regression elucidated that high BMD (P < 0.001, OR = 0.089) and high level of serum 25-OH-D3 (P = 0.012, OR = 0.877) were negatively correlated with the cemented vertebra recompression after PVP.

Conclusion: Decreased BMD and lower level of serum 25-OH-D3 might be two critical and significant risk factors for the height loss of cemented vertebrae after PVP.

Citing Articles

Risk factors for new vertebral fractures after percutaneous vertebroplasty or percutaneous kyphoplasty in the treatment of osteoporotic vertebral compression fractures.

Yang W, Zou K, Lin X, Yang Y, Chen T, Wu X Front Med (Lausanne). 2025; 12:1514894.

PMID: 39911860 PMC: 11794209. DOI: 10.3389/fmed.2025.1514894.


External validation of predictive models for new vertebral fractures following percutaneous vertebroplasty.

Dai X, Liao W, Xu F, Lu W, Xi X, Fang X Eur Spine J. 2024; .

PMID: 38713446 DOI: 10.1007/s00586-024-08274-x.


Regional differences in bone mineral density biomechanically induce a higher risk of adjacent vertebral fracture after percutaneous vertebroplasty: a case-comparative study.

Li J, Xie Y, Sun S, Xue C, Xu W, Xu C Int J Surg. 2023; 109(3):352-363.

PMID: 36912508 PMC: 10389488. DOI: 10.1097/JS9.0000000000000273.


Impact of Alendronate Sodium plus Elcatonin on Postoperative Bone Pain in Patients with Osteoporotic Fractures.

Wang B, Sun Y, Shi D, Han X, Liu N, Wang B Biomed Res Int. 2022; 2022:1213278.

PMID: 36119926 PMC: 9473873. DOI: 10.1155/2022/1213278.

References
1.
Lotan R, Smorgick Y, Anekstein Y, Rudik O, Prosso I, Hershkovich O . Kyphoplasty for Elderly Patients With Vertebral Compression Fractures-Do We Save Lives? Mortality Rates Analysis Comparison in a Long-Term Follow-Up Cohort. Global Spine J. 2021; 12(7):1443-1448. PMC: 9393975. DOI: 10.1177/2192568220982282. View

2.
Zhang L, Wang Q, Wang L, Shen J, Zhang Q, Sun C . Bone cement distribution in the vertebral body affects chances of recompression after percutaneous vertebroplasty treatment in elderly patients with osteoporotic vertebral compression fractures. Clin Interv Aging. 2017; 12:431-436. PMC: 5327848. DOI: 10.2147/CIA.S113240. View

3.
Martinez-Ferrer A, Blasco J, Carrasco J, Macho J, San Roman L, Lopez A . Risk factors for the development of vertebral fractures after percutaneous vertebroplasty. J Bone Miner Res. 2013; 28(8):1821-9. DOI: 10.1002/jbmr.1899. View

4.
McKiernan F, Faciszewski T, Jensen R . Reporting height restoration in vertebral compression fractures. Spine (Phila Pa 1976). 2003; 28(22):2517-21. DOI: 10.1097/01.BRS.0000092424.29886.C9. View

5.
Hodsman A, Bauer D, Dempster D, Dian L, Hanley D, Harris S . Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005; 26(5):688-703. DOI: 10.1210/er.2004-0006. View